Renal/Urology · PANCE / PANRE

Renal Cell Carcinoma (RCC)

Written & clinically reviewed by Ryan Busch, PA-C · Updated August 2026 · Report an error

Most common primary kidney malignancy; often incidental finding on imaging.

Also known as: RCC, renal cell carcinoma, kidney cancer, hypernephroma

Overview

A malignancy arising from renal tubular epithelium, most commonly the proximal convoluted tubule. Clear cell RCC is the predominant histologic subtype (~75%); other subtypes include papillary (~15%), chromophobe (~5%), and collecting duct.

Epidemiology

Most common primary renal malignancy in adults; ~76,000 new cases and ~13,000 deaths annually in the US. Male predominance 2:1. Peak incidence ages 60-70. Increasing incidence due to widespread cross-sectional imaging — most diagnoses now incidental.

Try two board-style Renal Cell Carcinoma questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1RenalMedium
A 55-year-old man presents with several months of intermittent gross hematuria and dull left flank pain. Exam reveals a firm, palpable mass in the left flank. CT of the abdomen and pelvis shows a 7-cm enhancing heterogeneous mass arising from the left kidney without evidence of metastatic disease. Renal function is normal. Which of the following is the most appropriate next step in management?
  • APercutaneous renal biopsy
  • BTyrosine kinase inhibitor therapy
  • CObservation with serial imaging
  • DSurgical nephrectomy
Reveal answer & full explanation
Correct answer: D — Surgical nephrectomy
  • APercutaneous renal biopsy
  • BTyrosine kinase inhibitor therapy
  • CObservation with serial imaging
  • DSurgical nephrectomy✓

Why Surgical nephrectomy is correct

  • Renal cell carcinoma (RCC) classic triad — hematuria, flank pain, and palpable mass — indicates advanced disease
  • CT enhancement confirms malignancy; biopsy is not routinely required preoperatively
  • For masses >4 cm, partial or radical nephrectomy is indicated; partial nephrectomy is preferred when feasible to preserve renal function
  • This patient has a 7-cm mass with no evidence of metastatic disease and normal renal function, making surgical resection the appropriate next step

Why the others are wrong

  • A) Percutaneous renal biopsy — not routinely required before surgery when CT enhancement is diagnostic for RCC
  • B) Tyrosine kinase inhibitor therapy — sunitinib and pazopanib (vascular endothelial growth factor receptor (VEGFR) inhibitors) and checkpoint inhibitors (nivolumab + ipilimumab) are used for metastatic RCC, not localized disease
  • C) Observation with serial imaging — not appropriate for a 7-cm enhancing renal mass without metastases in a surgical candidate
Question 2RenalMedium
A 60-year-old male smoker has hematuria and a 4-cm right kidney mass on CT. Biopsy shows clear cell histology. Which of the following paraneoplastic syndromes is most associated with this malignancy?
  • AErythrocytosis from ectopic erythropoietin
  • BHypothyroidism from immune cross-reactivity
  • CHypocalcemia from tumor calcium consumption
  • DCushing syndrome from ectopic adrenocorticotropic hormone (ACTH)
Reveal answer & full explanation
Correct answer: A — Erythrocytosis from ectopic erythropoietin
  • AErythrocytosis from ectopic erythropoietin✓
  • BHypothyroidism from immune cross-reactivity
  • CHypocalcemia from tumor calcium consumption
  • DCushing syndrome from ectopic adrenocorticotropic hormone (ACTH)

Why erythrocytosis from ectopic erythropoietin is correct

  • Renal cell carcinoma (RCC) classically produces ectopic erythropoietin (EPO), leading to erythrocytosis as the most associated paraneoplastic syndrome.
  • Other paraneoplastic syndromes of RCC include hypercalcemia (via parathyroid hormone-related protein (PTH-rP)), hypertension (via renin secretion), and Stauffer syndrome (paraneoplastic hepatic dysfunction without metastasis).

Why the others are wrong

  • Hypothyroidism from immune cross-reactivity — not a recognized paraneoplastic syndrome of RCC.
  • Hypocalcemia from tumor calcium consumption — RCC is associated with hypercalcemia (from PTH-rP), not hypocalcemia.
  • Cushing syndrome from ectopic adrenocorticotropic hormone (ACTH) — ectopic ACTH is classically associated with small cell lung cancer and carcinoid tumors, not RCC.

Additional high-yield points

  • RCC is the most common primary kidney cancer in adults.
  • Risk factors: smoking (most important), obesity, hypertension, von Hippel-Lindau disease, dialysis (acquired cystic disease), occupational exposures (cadmium, asbestos).
  • Histology: clear cell is the most common subtype.
  • Classic triad: hematuria, flank pain, palpable mass — present together in only 10% of cases.
  • Workup: CT abdomen/pelvis with contrast (RCC enhances), CT chest for metastases, bone scan if symptomatic.
  • Treatment: partial or radical nephrectomy; tyrosine kinase inhibitors and immunotherapy for metastatic disease.
  • Do not routinely biopsy renal masses due to tract seeding risk.
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Renal Cell Carcinoma (RCC) outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → Sign in
Free to start · No credit card · Cancel anytime

Risk factors

  • Smoking (2× risk; dose-dependent)
  • Obesity
  • Hypertension
  • Chronic kidney disease, dialysis-acquired cystic disease
  • Family history (5-8% hereditary)
  • Hereditary syndromes: von Hippel-Lindau (clear cell), hereditary papillary RCC (papillary type 1), Birt-Hogg-Dubé (chromophobe), tuberous sclerosis
  • Occupational: trichloroethylene, cadmium, asbestos
  • Acquired cystic disease in ESRD/dialysis

Pathophysiology

Clear cell RCC most commonly arises from loss of function of the von Hippel-Lindau (VHL) tumor suppressor on chromosome 3p, leading to constitutive activation of hypoxia-inducible factor (HIF) and downstream VEGF, PDGF, and other growth factor pathways. Tumors are highly vascular. Late metastases occur via hematogenous (lung, bone, liver, brain) and lymphatic spread; invasion of renal vein and inferior vena cava is characteristic.

Clinical presentation

Symptoms

  • Most patients asymptomatic — found incidentally on cross-sectional imaging
  • Classic triad (flank pain + hematuria + palpable mass) present in <10% and indicates advanced disease
  • Hematuria (gross or microscopic)
  • Flank pain or back pain
  • Constitutional symptoms: weight loss, fever, fatigue, night sweats
  • Paraneoplastic manifestations: hypercalcemia (PTHrP), polycythemia (EPO), HTN (renin), Stauffer syndrome (reversible hepatic dysfunction without metastases)
  • Symptoms of metastatic disease: bone pain, dyspnea, hemoptysis, neurologic deficits

Signs / physical exam

  • Palpable flank or abdominal mass (advanced disease)
  • Left-sided varicocele in male (new or non-decompressing supine) — suggests left renal vein involvement
  • Lower extremity edema if IVC involvement
  • Hepatomegaly with Stauffer syndrome
  • Findings of metastatic disease

Classic findings

Adult-onset varicocele on the LEFT side that does not decompress when supine suggests left renal vein involvement by RCC — image with CT.

Differential diagnosis

  • Simple renal cyst — Bosniak I — anechoic, thin-walled, no enhancement; benign and stable
  • Complex renal cyst (Bosniak II-IV) — Increasing complexity; Bosniak III-IV warrant biopsy or resection
  • Angiomyolipoma — Macroscopic fat on CT (low Hounsfield units); associated with tuberous sclerosis; bleeding risk if >4 cm
  • Oncocytoma — Benign tumor; difficult to distinguish from chromophobe RCC on imaging — often resected
  • Transitional cell carcinoma of upper tract — Centrally located in renal pelvis, smoking history; hematuria
  • Wilms tumor — Pediatric (median 3 years); palpable abdominal mass; WT1 mutation
  • Renal abscess — Fever, leukocytosis, recent UTI; fluid collection with rim enhancement

Diagnostic workup

Diagnostic criteria

Tissue diagnosis (biopsy or surgical pathology) confirms RCC. Most clinically apparent tumors are resected without prior biopsy when imaging is characteristic. Biopsy increasingly used for small renal masses to inform active surveillance vs intervention. Staged by TNM (AJCC 8th edition).

Labs

  • CBC (anemia of chronic disease or polycythemia)
  • BMP with calcium (hypercalcemia common)
  • LFTs (Stauffer syndrome)
  • Urinalysis (hematuria)
  • LDH (prognostic marker for advanced disease)
  • No reliable tumor marker for screening

Imaging

  • Contrast-enhanced CT abdomen/pelvis — initial imaging of choice; characterizes mass and stages
  • RCC enhances on arterial phase, washes out on delayed phase
  • MRI — alternative if CT contraindicated; better for IVC thrombus characterization
  • Renal ultrasound often initial — distinguishes solid from cystic mass
  • Chest CT — staging for pulmonary metastases (most common metastatic site)
  • Bone scan if elevated alkaline phosphatase or bone pain
  • Brain MRI if neurologic symptoms

Diagnostic algorithm

Bosniak CategoryDescriptionMalignancy RiskManagement
ISimple cyst — thin wall, no septa, no enhancement~0%No follow-up
IIFew hairline septa, fine calcification~0%No follow-up
IIFMinimally complex; needs follow-up~5%Surveillance imaging
IIIThick or irregular septa, enhancement~50%Resection (partial nephrectomy)
IVClearly enhancing soft tissue~90%Resection
Bosniak classification of renal cystic lesions guides management of cystic kidney masses.

Treatment

First-line

  • Localized disease (Stage I-III):
  • Partial nephrectomy — standard for T1a tumors (<4 cm) and feasible T1b (4-7 cm); nephron-sparing
  • Radical nephrectomy — for larger tumors (T2+) or when partial not feasible; en bloc with adrenal if upper pole or adrenal involvement
  • Active surveillance — small renal masses <2-3 cm in elderly or significant comorbidity; serial imaging
  • Thermal ablation (cryoablation, radiofrequency) — for small tumors in poor surgical candidates
  • Adjuvant pembrolizumab — for high-risk resected RCC (KEYNOTE-564)
  • Metastatic disease (Stage IV):
  • First-line immune checkpoint inhibitor combinations: ipilimumab + nivolumab (intermediate/poor risk), or pembrolizumab + axitinib, nivolumab + cabozantinib, lenvatinib + pembrolizumab
  • Cytoreductive nephrectomy — selected patients with good performance status, low metastatic burden
  • Stereotactic body radiation (SBRT) for oligometastatic disease or palliation

Second-line / adjunct

  • Tyrosine kinase inhibitors (VEGFR-targeted): sunitinib, pazopanib, cabozantinib, axitinib, lenvatinib
  • mTOR inhibitors: everolimus, temsirolimus
  • Belzutifan (HIF-2α inhibitor) — for VHL-associated RCC and after prior TKI/ICI
  • Continue follow-up imaging post-treatment (CT chest/abdomen every 6-12 months)
  • Genetic counseling if young onset, bilateral/multifocal, family history, or syndromic features

Complications

  • Metastatic disease — lung most common, followed by bone, liver, brain, adrenal
  • Paraneoplastic syndromes (hypercalcemia, polycythemia, Cushing-like, Stauffer)
  • Vena cava tumor thrombus (clear cell RCC characteristic)
  • Post-operative: CKD (nephron loss), bleeding, urine leak, infection
  • Treatment toxicities: hypertension (VEGF), immune-related adverse events (ICI)
  • Renal vein invasion → varicocele, varices, embolism risk

PANCE pearls

  • Classic triad of flank pain + hematuria + palpable mass occurs in <10% — and when it does, indicates locally advanced disease.
  • Left-sided varicocele in an adult man that does NOT decompress when lying down = consider left renal vein invasion by RCC. (Right testicular vein drains directly to IVC; left drains to left renal vein.)
  • Paraneoplastic syndromes are common: PTHrP (hypercalcemia), EPO (polycythemia), renin (HTN), Stauffer syndrome (hepatic dysfunction without metastases).
  • Bosniak classification: I-II = benign; IIF = follow; III = ~50% malignant (resect); IV = ~90% malignant (resect).
  • RCC is the most common solid tumor associated with paraneoplastic polycythemia (EPO-mediated erythrocytosis); other causes include HCC and cerebellar hemangioblastoma.
  • Partial nephrectomy is preferred over radical when feasible to preserve renal function — important for long-term cardiovascular and CKD outcomes.

References

  • AUA 2021 — Renal Mass and Localized Renal Cancer: AUA Guideline (Campbell et al., J Urol 2021)
  • NCCN 2024 — NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer Version 2024
  • KEYNOTE-564 — Pembrolizumab as Post Nephrectomy Adjuvant Therapy for RCC (Choueiri et al., NEJM 2021)

Practice Renal/Urology questions on FirstPassPA

Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Related Renal/Urology diagnoses

Acute Kidney Injury (AKI)Chronic Kidney Disease (CKD)End-Stage Renal Disease and DialysisNephrotic SyndromeNephritic SyndromeIgA NephropathyAcute Tubular Necrosis (ATN)Acute Interstitial Nephritis (AIN)Post-Streptococcal Glomerulonephritis (PSGN)Autosomal Dominant Polycystic Kidney Disease (ADPKD)Urolithiasis (Kidney Stones)Acute Cystitis (Uncomplicated UTI)Acute PyelonephritisBladder Cancer

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.